Literature DB >> 6405475

Infections caused by Pseudomonas aeruginosa.

G P Bodey, R Bolivar, V Fainstein, L Jadeja.   

Abstract

Pseudomonas aeruginosa has emerged as an important pathogen during the past two decades. It causes between 10% and 20% of infections in most hospitals. Pseudomonas infection is especially prevalent among patients with burn wounds, cystic fibrosis, acute leukemia, organ transplants, and intravenous-drug addiction. P. aeruginosa is a common nosocomial contaminant, and epidemics have been traced to many items in the hospital environment. Patients who are hospitalized for extended periods are frequently colonized by this organism and are at increased risk of developing infection. The most serious infections include malignant external otitis, endophthalmitis, endocarditis, meningitis, pneumonia, and septicemia. The likelihood of recovery from pseudomonas infection is related to the severity of the patient's underlying disease process. The introduction of the antipseudomonal aminoglycosides and penicillins has improved substantially the prognosis of these infections. Ticarcillin and carbenicillin have been especially beneficial in neutropenic patients; however, prompt institution of therapy is mandatory for optimal benefit. Many new drugs with antipseudomonal activity, including penicillins, cephalosporins, and other beta-lactams, have been introduced in recent years and offer the potential for new approaches to therapy for these infections.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6405475     DOI: 10.1093/clinids/5.2.279

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  296 in total

1.  Pseudomonas aeruginosa cell-to-cell signaling is required for virulence in a model of acute pulmonary infection.

Authors:  J P Pearson; M Feldman; B H Iglewski; A Prince
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

2.  Pseudomonas aeruginosa exoenzyme S is a biglutamic acid ADP-ribosyltransferase.

Authors:  J Radke; K J Pederson; J T Barbieri
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

3.  EVALUATION OF HOSPITAL ACQUIRED PSEUDOMONAS INFECTION IN PARAPLEGIC AND ORTHOPAEDIC CASES.

Authors:  K K Lahiri
Journal:  Med J Armed Forces India       Date:  2017-06-26

4.  Pharmacodynamic parameters of aminoglycosides and their effect on exoenzymes of Pseudomonas aeruginosa.

Authors:  A Hostacká
Journal:  Folia Microbiol (Praha)       Date:  1996       Impact factor: 2.099

5.  Genome fingerprinting by pulsed-field gel electrophoresis and ribotyping to differentiate Pseudomonas aeruginosa serotype O11 strains.

Authors:  C L Poh; C C Yeo; L Tay
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-09       Impact factor: 3.267

6.  Characteristics of Pseudomonas aeruginosa strains causing septicemia in a Spanish hospital 1981-1990.

Authors:  F Vázquez; M C Mendoza; M H Villar; A Vindel; F J Méndez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-08       Impact factor: 3.267

7.  Structural and genetic characterization of glycosylation of type a flagellin in Pseudomonas aeruginosa.

Authors:  M Schirm; S K Arora; A Verma; E Vinogradov; P Thibault; R Ramphal; S M Logan
Journal:  J Bacteriol       Date:  2004-05       Impact factor: 3.490

8.  Transcription of the oprF gene of Pseudomonas aeruginosa is dependent mainly on the SigX sigma factor and is sucrose induced.

Authors:  Emeline Bouffartigues; Gwendoline Gicquel; Alexis Bazire; Manjeet Bains; Olivier Maillot; Julien Vieillard; Marc G J Feuilloley; Nicole Orange; R E W Hancock; Alain Dufour; Sylvie Chevalier
Journal:  J Bacteriol       Date:  2012-06-08       Impact factor: 3.490

9.  Tobramycin and bicarbonate synergise to kill planktonic Pseudomonas aeruginosa, but antagonise to promote biofilm survival.

Authors:  Karishma S Kaushik; Jake Stolhandske; Orrin Shindell; Hugh D Smyth; Vernita D Gordon
Journal:  NPJ Biofilms Microbiomes       Date:  2016-05-25       Impact factor: 7.290

10.  Pseudomonas elastase acts as a virulence factor in burned hosts by Hageman factor-dependent activation of the host kinin cascade.

Authors:  I A Holder; A N Neely
Journal:  Infect Immun       Date:  1989-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.